According to the Zepbound label, the most frequent include nausea (24-29%), diarrhea (18-24%), vomiting (8-10%), and constipation (16-17%)
Retatrutides triple agonist activity, targeting GLP-1, GIP, and glucagon receptors, enhances both weight loss and metabolic improvements beyond what is typically observed with GLP-1-only therapy
Our weight loss programs combine medically supervised treatment with compassionate support, ensuring that you feel empowered throughout your journey
hormone imbalances contribute to weight gain, and excess weight affects hormone balance
For semaglutide, clinically significant levels persist for approximately three to five half-lives after the last dose, which is 21-35 days